Latest Blog Posts Tagged "Glutamate Receptors"
February 10, 2017
MJFF funded early research of this novel drug candidate, mGluR4, helping remove financial and other barriers to advance its testing.
December 11, 2012
Biotie Therapies is announcing positive clinical study results into a novel approach to treat symptoms of Parkinson's: In a phase 2b trial, tozadenant was found to significantly limit "off periods."
Todd Sherer Presents at Congressional Briefing on The Foundation's Role in the Drug Development Process
November 29, 2012
Michael J. Fox Foundation CEO Todd Sherer, PhD, was invited to discuss the recent collaboration between Vanderbilt University and the Bristol-Myers Squibb in a congressional briefing Wednesday.
November 20, 2012
By seizing the risk, the Foundation helps awardees secure funds needed to develop novel Parkinson's drugs.
October 10, 2012
American scientists Robert Lefkowitz and Brian Kobilka were today awarded the Nobel Prize in Chemistry for discoveries surrounding receptors that play a role in some medical conditions, including PD.
September 21, 2012
Vanderbilt-Bristol-Myers Squibb collaboration leveraging MJFF investment could push new paradigm of symptomatic treatment to the clinic by 2013
December 13, 2011
With MJFF funding, Jeff Conn, PhD, at Vanderbilt University has accelerated a promising new PD treatment toward the clinic. Instead of targeting the dopamine system, his approach focuses on the glutam...